MIAMI, July 01, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, continues its ongoing commitment to strengthen and broaden its capabilities as Dr. Muneer A. Ali joined the Company’s Medical Advisory Board. Dr. Ali will collaborate with other members of Ehave’s Medical Advisory Board to assist and advise the Company on human trials for its cognitive and psychedelic opportunities, as well as assist and advise the Company on mental health analytical platforms.
Dr. Muneer A. Ali is a clinical psychiatrist who is the Associate Medical Director and a Child, Adolescent and Adult Psychiatrist at Amen Clinics, Inc. in Atlanta, GA. Dr. Ali takes a particular interest in ADHD, anxiety disorders, and substance use disorders. He completed his training in Psychiatry at the State University of New York, completed a Fellowship in Child and Adolescent Psychiatry, and served as Chief Fellow in his final year. Dr. Ali is double Board-certified in Adult and Child/Adolescent Psychiatry through the American Board of Psychiatry and Neurology.
Dr. Ali is a diplomate of the American Board of Psychiatry and Neurology in General, Child, and Adolescent Psychiatry and holds STATE MEDICAL LICENSES in Alabama, Florida, Georgia, Kentucky, North Carolina, South Carolina, and Tennessee. Dr. Ali's work has been published in professional journals such as The Neuroscience of Depression: Genetics, Cell Biology, Neurology, Behavior, and Diet, and he has presented at the Talk About Curing Autism Southeast Regional Conference. Dr. Ali has won such prestigious awards as the 2013 American Academy of Child and Adolescent Psychiatry Educational Outreach Program Award and the 2009 TOUCH Award from the College of Osteopathic Medicine at Nova Southeastern University. In addition to his professional accolades, Dr. Ali has taught graduate level courses at the State University of New York at Buffalo. He received his Doctor of Medicine from Nova Southeastern University and performed his postgraduate residency at the State University of New York at Buffalo.
Ehave's Chief Medical Officer, Dr. Jeffrey Kamlet, also commented on the Board’s recent expansion, saying, “Dr. Ali's professional experience will provide us with tremendous insight. I believe his leadership experience, insight and advice will be invaluable as Ehave begins human trials for its cognitive and psychedelic opportunities."
Dr. Muneer A. Ali said, "I am delighted to be joining Ehave's Medical Advisory Board. Ehave is committing its resources to making life better for those individuals suffering from mental health issues. I look forward to working closely with the Ehave team to facilitate advancement of their efforts."
"We are incredibly excited to welcome Dr. Ali as the newest member of our Medical Advisory Board. With his wisdom and experience as a thought leader, Dr. Ali will be a welcome addition to our already impressive Medical Advisory Board. I look forward to working closely with Dr. Ali and our entire team as we advance our mission of delivering psychedelic-inspired therapies to patients in need."
About Ehave, Inc.
Ehave, Inc. is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, psychedelics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes meeting privacy and HIPAA & GDPR Compliant. Our main product is the Ehave Dashboard which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insight using Blockchain technology. The Ehave dashboard offers Offline Encrypted Digital Records Empowering Healthcare providers and patients and it's a powerful machine learning and artificial intelligence platform using artificial intelligence to extract deep insights from audio, video and text to improve research with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools.
Forward-Looking Statement Disclaimer
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website, http://www.sec.gov.
For Investors Relations, please contact:
Gabe Rodriguez
Phone: (623) 261-9046
Email: ir@ehave.com